Chérifa Taleb

415 total citations
19 papers, 281 citations indexed

About

Chérifa Taleb is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Geriatrics and Gerontology. According to data from OpenAlex, Chérifa Taleb has authored 19 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 3 papers in Geriatrics and Gerontology. Recurrent topics in Chérifa Taleb's work include Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Chérifa Taleb is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Chérifa Taleb collaborates with scholars based in France. Chérifa Taleb's co-authors include Thierry Landré, C. Chouaïd, M Thomas, A. Kettaneh, Patrick Nicolas, Kader Chouahnia, G. Des Guetz, Jean‐Baptiste Assié, Liliane Gattegno and Jérôme Stirnemann and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Nutrients.

In The Last Decade

Chérifa Taleb

16 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chérifa Taleb France 8 115 84 79 55 39 19 281
V. D’Souza United Kingdom 8 36 0.3× 77 0.9× 58 0.7× 29 0.5× 59 1.5× 16 278
Piergianni Biondi Italy 9 88 0.8× 18 0.2× 44 0.6× 79 1.4× 110 2.8× 12 299
Chiara Sonato Italy 9 118 1.0× 54 0.6× 32 0.4× 91 1.7× 76 1.9× 18 356
Ryuta Shigefuku Japan 10 53 0.5× 37 0.4× 32 0.4× 43 0.8× 25 0.6× 41 294
Satish Shah United States 7 31 0.3× 66 0.8× 64 0.8× 25 0.5× 17 0.4× 19 172
Kenjiro Ishii Japan 10 42 0.4× 132 1.6× 11 0.1× 147 2.7× 18 0.5× 28 238
Oliver Ng United Kingdom 10 103 0.9× 44 0.5× 11 0.1× 62 1.1× 14 0.4× 20 327
Lieven Goeman Belgium 11 38 0.3× 161 1.9× 28 0.4× 74 1.3× 27 0.7× 24 313
M Renoux France 8 40 0.3× 33 0.4× 10 0.1× 13 0.2× 33 0.8× 23 286
John Vassiliou Greece 10 65 0.6× 71 0.8× 51 0.6× 211 3.8× 48 1.2× 16 348

Countries citing papers authored by Chérifa Taleb

Since Specialization
Citations

This map shows the geographic impact of Chérifa Taleb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chérifa Taleb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chérifa Taleb more than expected).

Fields of papers citing papers by Chérifa Taleb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chérifa Taleb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chérifa Taleb. The network helps show where Chérifa Taleb may publish in the future.

Co-authorship network of co-authors of Chérifa Taleb

This figure shows the co-authorship network connecting the top 25 collaborators of Chérifa Taleb. A scholar is included among the top collaborators of Chérifa Taleb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chérifa Taleb. Chérifa Taleb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Martinez‐Tapia, Claudia, Tristan Cudennec, Chérifa Taleb, et al.. (2023). Prevalence of Four Sarcopenia Criteria in Older Patients with Cancer, and Their Predictive Value for 6-Month Mortality: The NutriAgeCancer National Prospective Cohort Study. Nutrients. 15(6). 1508–1508. 5 indexed citations
3.
4.
Melki, Ronald, et al.. (2021). Acute pancreatitis induced by valproic acid. European Psychiatry. 64(S1). S642–S642.
5.
Landré, Thierry, Jean‐Baptiste Assié, Kader Chouahnia, et al.. (2021). Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials. Cancer Immunology Immunotherapy. 71(3). 719–726. 50 indexed citations
6.
7.
Landré, Thierry, Jean‐Baptiste Assié, Kader Chouahnia, et al.. (2021). Anti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials.. Journal of Clinical Oncology. 39(15_suppl). 9025–9025. 1 indexed citations
8.
Landré, Thierry, Gaëtan Des Guetz, Kader Chouahnia, et al.. (2019). First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers. Journal of Cancer Research and Clinical Oncology. 146(2). 441–448. 9 indexed citations
9.
10.
Landré, Thierry, E. Maillard, Chérifa Taleb, et al.. (2018). Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. International Journal of Colorectal Disease. 33(8). 1125–1130. 11 indexed citations
11.
Landré, Thierry, et al.. (2017). Inhibiteurs de “check point”, quelles perspectives pour les patients âgés ?. Soins Gérontologie. 22(127). 30–33. 2 indexed citations
12.
Landré, Thierry, Thomas Aparicio, Patrick Nicolas, et al.. (2017). Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.. Journal of Clinical Oncology. 35(15_suppl). e15034–e15034.
13.
Landré, Thierry, Chérifa Taleb, Patrick Nicolas, & G. Des Guetz. (2016). Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?. Journal of Clinical Oncology. 34(15_suppl). 3070–3070. 25 indexed citations
14.
Landré, Thierry, Bernard Uzzan, Patrick Nicolas, et al.. (2015). Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. International Journal of Colorectal Disease. 30(10). 1305–1310. 20 indexed citations
15.
Landré, Thierry, Patrick Nicolas, Bernard Uzzan, et al.. (2015). Is there a benefit of TKIs among the elderly compared with younger patients in non-small cell lung cancer? a meta-analysis.. Journal of Clinical Oncology. 33(15_suppl). e20515–e20515. 1 indexed citations
16.
Fain, Olivier, Jacques Pariès, Gisèle Le Moël, et al.. (2003). Hypovitaminosis C in hospitalized patients. European Journal of Internal Medicine. 14(7). 419–425. 89 indexed citations
17.
Fain, Olivier, Véronique Joly, Zora Marjanovic, et al.. (2001). UN LOGICIEL INFORMATIQUE POUR LE SUIVI DES PATIENTS SOUS TRAITEMENT ANTI-TUBERCULEUX. 4 indexed citations
18.
Fain, O., Olivier Lortholary, P Babinet, et al.. (2000). Extrapulmonary tuberculosis in the northeastern suburbs of Paris: 141 cases. European Journal of Internal Medicine. 11(3). 145–150. 42 indexed citations
19.
Fain, Olivier, et al.. (1998). Évaluation de la carence en vitamine C dans un service de médecine interne en Seine-Saint-Denis en 1997. La Revue de Médecine Interne. 19. 61S–61S. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. D’Souza Breakdown of academic impact, for papers by Piergianni Biondi Breakdown of academic impact, for papers by Chiara Sonato Breakdown of academic impact, for papers by Ryuta Shigefuku Breakdown of academic impact, for papers by Satish Shah Breakdown of academic impact, for papers by Kenjiro Ishii Breakdown of academic impact, for papers by Oliver Ng Breakdown of academic impact, for papers by Lieven Goeman Breakdown of academic impact, for papers by M Renoux Breakdown of academic impact, for papers by John Vassiliou
Rankless by CCL
2026